Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 146

1.

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, Eisen T, Horwich A; ESMO Guidelines Working Group.

Ann Oncol. 2014 Sep;25 Suppl 3:iii49-iii56. doi: 10.1093/annonc/mdu259. No abstract available.

PMID:
25210086
[PubMed - in process]
2.

Prostate Stereotactic Body Radiotherapy - First UK Experience.

Tree AC, Ostler P, Hoskin P, Dankulchai P, Nariyangadu P, Hughes RJ, Wells E, Taylor H, Khoo VS, van As NJ.

Clin Oncol (R Coll Radiol). 2014 Sep 3. pii: S0936-6555(14)00297-0. doi: 10.1016/j.clon.2014.08.007. [Epub ahead of print]

PMID:
25193299
[PubMed - as supplied by publisher]
3.

Incidence and predictors of side-branch compromise in primary percutaneous coronary intervention for acute myocardial infarction.

Khoo V, Shen L, Khoo V, Loo G, Richards M, Yeo TC, Lee CH.

J Invasive Cardiol. 2014 Jul;26(7):297-302.

PMID:
24993985
[PubMed - in process]
Free Article
4.

Dose-volume response in acute dysphagia toxicity: Validating QUANTEC recommendations into clinical practice for head and neck radiotherapy.

Anderson NJ, Wada M, Schneider-Kolsky M, Rolfo M, Joon DL, Khoo V.

Acta Oncol. 2014 Jul 1:1-7. [Epub ahead of print]

PMID:
24980044
[PubMed - as supplied by publisher]
5.

Radiotherapy for renal-cell carcinoma.

De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, Briganti A, Fonteyne V, Van Vulpen M, Lumen N, Spahn M, Mareel M.

Lancet Oncol. 2014 Apr;15(4):e170-7. doi: 10.1016/S1470-2045(13)70569-2. Review.

PMID:
24694640
[PubMed - indexed for MEDLINE]
6.

MRI scans significantly change target coverage decisions in radical radiotherapy for prostate cancer.

Chang JH, Lim Joon D, Nguyen BT, Hiew CY, Esler S, Angus D, Chao M, Wada M, Quong G, Khoo V.

J Med Imaging Radiat Oncol. 2014 Apr;58(2):237-43. doi: 10.1111/1754-9485.12107. Epub 2013 Aug 29.

PMID:
24690247
[PubMed - in process]
7.

Comparison of setup accuracy and intrafraction motion using stereotactic frame versus 3-point thermoplastic mask-based immobilization for fractionated cranial image guided radiation therapy.

Rosenfelder NA, Corsini L, McNair H, Pennert K, Aitken A, Lamb CM, Long M, Clarke E, Murcia M, Schick U, Burke K, Ashley S, Khoo V, Brada M.

Pract Radiat Oncol. 2013 Jul-Sep;3(3):171-9. doi: 10.1016/j.prro.2012.06.004. Epub 2012 Jul 19.

PMID:
24674361
[PubMed]
8.

Determination of the severity of underlying lesions in acute myocardial infarction on the basis of collateral vessel development.

Khoo V, Shen L, Zhao L, Khoo V, Loo G, Richards AM, Yeo TC, Lee CH.

Coron Artery Dis. 2014 Sep;25(6):493-7. doi: 10.1097/MCA.0000000000000115.

PMID:
24667127
[PubMed - in process]
9.

Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.

Dearnaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD, Aird EG, Bottomley D, Huddart RA, Jose CC, Matthews JH, Millar JL, Murphy C, Russell JM, Scrase CD, Parmar MK, Sydes MR.

Lancet Oncol. 2014 Apr;15(4):464-73. doi: 10.1016/S1470-2045(14)70040-3. Epub 2014 Feb 26.

PMID:
24581940
[PubMed - indexed for MEDLINE]
Free Article
10.

Is biochemical relapse-free survival after profoundly hypofractionated radiotherapy consistent with current radiobiological models?

Tree AC, Khoo VS, van As NJ, Partridge M.

Clin Oncol (R Coll Radiol). 2014 Apr;26(4):216-29. doi: 10.1016/j.clon.2014.01.008. Epub 2014 Feb 12.

PMID:
24529742
[PubMed - in process]
11.

Telomere length shows no association with BRCA1 and BRCA2 mutation status.

Killick E, Tymrakiewicz M, Cieza-Borrella C, Smith P, Thompson DJ, Pooley KA, Easton DF, Bancroft E, Page E, Leongamornlert D; IMPACT collaborators, Kote-Jarai Z, Eeles RA.

PLoS One. 2014 Jan 29;9(1):e86659. doi: 10.1371/journal.pone.0086659. eCollection 2014.

PMID:
24489760
[PubMed - in process]
Free PMC Article
12.

Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study.

Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón Y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E; The IMPACT Collaborators, Moss S, Eeles RA.

Eur Urol. 2014 Jan 15. pii: S0302-2838(14)00004-9. doi: 10.1016/j.eururo.2014.01.003. [Epub ahead of print]

PMID:
24484606
[PubMed - as supplied by publisher]
Free PMC Article
13.

Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma.

Chang JH, Lim Joon D, Lee ST, Hiew CY, Esler S, Gong SJ, Wada M, Clouston D, O'Sullivan R, Goh YP, Tochon-Danguy H, Chan JG, Bolton D, Scott AM, Khoo V, Davis ID.

Eur Radiol. 2014 Mar;24(3):715-22. doi: 10.1007/s00330-013-3045-1. Epub 2013 Nov 6.

PMID:
24192979
[PubMed - in process]
14.

Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method?

Tree A, Jones C, Sohaib A, Khoo V, van As N.

Radiat Oncol. 2013 Oct 2;8(1):228. doi: 10.1186/1748-717X-8-228.

PMID:
24088319
[PubMed - in process]
Free PMC Article
15.

Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up.

Creak A, Hall E, Horwich A, Eeles R, Khoo V, Huddart R, Parker C, Griffin C, Bidmead M, Warrington J, Dearnaley D.

Br J Cancer. 2013 Aug 6;109(3):651-7. doi: 10.1038/bjc.2013.394. Epub 2013 Jul 23.

PMID:
23880826
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Clinical implementation of adaptive hypofractionated bladder radiotherapy for improvement in normal tissue irradiation.

McDonald F, Lalondrelle S, Taylor H, Warren-Oseni K, Khoo V, McNair HA, Harris V, Hafeez S, Hansen VN, Thomas K, Jones K, Dearnaley D, Horwich A, Huddart R.

Clin Oncol (R Coll Radiol). 2013 Sep;25(9):549-56. doi: 10.1016/j.clon.2013.06.001. Epub 2013 Jul 21.

PMID:
23880296
[PubMed - indexed for MEDLINE]
17.

Biological dose escalation and hypofractionation: what is there to be gained and how will it best be done?

Tree AC, Alexander EJ, Van As NJ, Dearnaley DP, Khoo V.

Clin Oncol (R Coll Radiol). 2013 Aug;25(8):483-98. doi: 10.1016/j.clon.2013.05.003. Epub 2013 Jun 27. Review.

PMID:
23810749
[PubMed - indexed for MEDLINE]
18.

Prostate cancer: current status, new developments and applications in radiotherapy.

Khoo V, Loblaw DA.

Clin Oncol (R Coll Radiol). 2013 Aug;25(8):449-50. doi: 10.1016/j.clon.2013.05.004. Epub 2013 Jun 10. No abstract available.

PMID:
23756325
[PubMed - indexed for MEDLINE]
19.

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.

Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Røder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC; COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Kote-Jarai Z, Easton DF.

Nat Genet. 2013 Apr;45(4):385-91, 391e1-2. doi: 10.1038/ng.2560.

PMID:
23535732
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Letter in response to Dearnaley et al. letter regarding paper: Evaluating the efficacy of statins and angiotensin converting enzyme-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies.

Wedlake LJ, Silia F, Benton B, Lalji A, Blake P, Tait D, Khoo VS, Andreyev HJ.

Eur J Cancer. 2013 May;49(7):1781-2. doi: 10.1016/j.ejca.2013.01.020. Epub 2013 Mar 7. No abstract available.

PMID:
23473615
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk